Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04456699
Title Efficacy and Safety of Olaparib, Olaparib + Bevacizumab Compared to Bevacizumab + 5-Fluorouracil (FU)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

colorectal adenocarcinoma

Therapies

Bevacizumab + Olaparib

Bevacizumab + Fluorouracil

Olaparib

Age Groups: adult | senior
Covered Countries USA | FRA | ESP | DEU | CAN | BEL


No variant requirements are available.